Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly

The Danish company has been battling it out with US rival Eli Lilly, with each developing newer medicines to turbocharge weight loss and diabetes results since the approval of Nordisk’s Ozempic in 2017. The job cuts announced by Novo Nordisk Wednesday amount to more than 11% of its global workforce...

Redirecting to full article...